A tiny peptide, composed of just four amino acids, is showing remarkable promise in preclinical studies as a potential treatment to limit brain damage following traumatic injury. Dubbed CAQK, the compound demonstrated a protective effect in animal models, reducing inflammation, cell death, and improving functional recovery after injury. This research offers a glimmer of hope in a field where effective treatments for traumatic brain injury (TBI) remain elusive.
The findings, published in the journal EMBO Molecular Medicine, stem from a collaborative effort led by Aivocode, a biotechnology company spun out of the Sanford Burnham Prebys Institute, in partnership with the Institute for Advanced Chemistry of Catalonia (IQAC) of the Spanish National Research Council (CSIC) and the University of California, Davis. Researchers found that CAQK, when administered intravenously shortly after injury in both mice and pigs, actively migrated to the damaged areas of the brain.
This targeted delivery is key. CAQK is attracted to proteins that become more abundant in injured brain tissue, essentially honing in on the site of damage. Once there, the peptide appears to mitigate the secondary cascade of events that exacerbate injury – namely, inflammation and cell death. The team observed smaller lesion sizes in mice treated with CAQK compared to control groups, alongside improvements in behavioral and memory tests. Importantly, no significant toxicity was observed during the study.
A New Approach to a Complex Problem
Traumatic brain injury, often resulting from car accidents, falls, or assaults, affects an estimated around 200 people per 100,000 inhabitants each year in the United States, according to the Centers for Disease Control and Prevention. Current clinical care focuses primarily on stabilizing patients – managing intracranial pressure and ensuring adequate blood flow – but lacks therapies specifically designed to halt the underlying brain damage.
“The current interventions for treating acute brain injury aim to stabilize the patient by reducing intracranial pressure and maintaining blood flow, but Notice no approved drugs to stop the damage and secondary effects of these injuries,” explained Dr. Pablo Scodeller, a researcher at IQAC-CSIC and co-author of the study. The lack of effective treatments underscores the urgent need for innovative approaches, and CAQK represents a potentially significant step forward.
Building on Years of Research
The discovery of CAQK’s therapeutic potential wasn’t accidental. It builds upon earlier work dating back to 2016, published in Nature Communications. Researchers, including Aman P. Mann and Pablo Scodeller working in Dr. Erkki Ruoslahti’s lab at Sanford Burnham Prebys, initially identified CAQK as a peptide capable of locating injured areas within the mouse brain. At that time, the peptide was envisioned as a delivery vehicle for other drugs. However, this new research reveals that CAQK itself possesses therapeutic properties.
The team utilized a technique called peptide-phage display – a large-scale screening method – to identify molecules that bind to specific tissues. This process allowed them to pinpoint CAQK’s affinity for injured brain regions. Further investigation revealed that CAQK binds to glycoproteins, proteins attached to sugars, which increase in concentration following brain trauma and are part of the extracellular matrix, the structural support surrounding brain cells.
From Mice and Pigs to Potential Human Trials
The success observed in mice was replicated in pig models, which have brains more anatomically similar to humans than mice. This represents a crucial step, as results that translate from mice to pigs are more likely to translate to humans. The intravenous administration of CAQK allowed for widespread distribution throughout the brain, reaching damaged tissues efficiently.
Aivocode, founded by Mann, Sazid Hussain, and Ruoslahti – all authors of the current study – is now preparing to seek authorization from the U.S. Food and Drug Administration (FDA) to initiate Phase I clinical trials in humans. While a specific timeline hasn’t been announced, the company highlights CAQK’s small size and ease of manufacturing as advantages. Smaller peptides are generally easier to synthesize and exhibit better tissue penetration, making them attractive drug candidates.
“What’s exciting is that, in addition to proving highly effective, it’s a very simple compound — a short peptide that is easy to synthesize safely at large scale. Peptides with these characteristics show good tissue penetration and are non-immunogenic,” Scodeller concluded.
Looking Ahead
The path from promising preclinical results to approved therapies is long and complex. Phase I trials will focus on assessing the safety and tolerability of CAQK in a small group of healthy volunteers. Subsequent phases will evaluate its efficacy in patients with traumatic brain injury. The success of these trials will determine whether CAQK can ultimately fulfill its potential as a life-changing treatment for those affected by this devastating condition. Aivocode has not yet announced a timeline for submitting its application to the FDA, but the company is actively preparing for the next stage of development.
If you or someone you know has experienced a traumatic brain injury, resources are available. The Brain Injury Association of America offers support and information at https://www.biausa.org/.
Share your thoughts on this promising research in the comments below, and share this article with anyone who might be interested in learning more about advancements in traumatic brain injury treatment.
Related reading
